Figure 1.

Kaplan Meier overall survival analysis by tumor sidedness and receipt of therapy. Left‐sided tumours demonstrated superior survival when treated with bevacizumab [HR 0.58 (95% CI 0.43‐0.78)] (Panel A) and when not treated by bevacizumab [HR 0.73 (95% CI 0.64‐0.82)] (Panel B). There was no association between bevacizumab and sidedness and survival (P = 0.195). Left‐sided KRAS wt tumors had superior survival when treated with EGFRIs [HR 0.38 (95% CI 0.22‐0.64)] (Panel C) and in the absence of treatment by EGFRIs [HR 0.72 (95% CI 0.64‐0.80)] (Panel D). P‐values in the figures indicate the comparison of sidedness in the treatment groups. There was a significant interaction between sidedness and EGFRI therapy on overall survival (P = 0.017), with a greater effect seen left‐sided tumors